Role of c-Met in Cancer: Emphasis on Lung Cancer

Seminars in Oncology

Volumn 36, Issue SUPPL. 1, 2009, Pages

  Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMG 102; ARQ 197; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GSK 1363089; JNJ 38877605; MGCD 265; MITOGEN ACTIVATED PROTEIN KINASE; MK 2461; MONOCLONAL ANTIBODY; MP 470; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; OA 505; PAXILLIN; PF 02341066F; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR INHIBITOR; SGX 523; UNCLASSIFIED DRUG; XL 880;

APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CELL CYCLE; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CAENORHABDITIS ELEGANS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 64849102583     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.02.008     Document Type: Article

References (52)

1. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4 (2003) 915-925
2. Zhang Y.W., and Vande Woude G.F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88 (2003) 408-417
3. Rosario M., and Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13 (2003) 328-335
4. Zillhardt M, Sawada K, Jagadeeswaran S, Temkin S, Yamada D, Buller R, et al. The c-Met/VEGFR2 inhibitor, XL880, inhibits ovarian cancer cell growth [abstract]. AACR Meeting Abstracts. 2008;4839.
5. Bardelli A., Ponzetto C., and Comoglio P.M. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J Biotechnol 37 (1994) 109-122
6. Christensen J.G., Burrows J., and Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225 (2005) 1-26
7. Hepatocyte growth factor/scatter factor, Met and cancer references. http://www.vai.org/met/ Accessed December 22, 2008
8. Graveel C., Su Y., Koeman J., Wang L.M., Tessarollo L., Fiscella M., et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101 (2004) 17198-17203
9. Cheng T.L., Chang M.Y., Huang S.Y., Sheu C.C., Kao E.L., Cheng Y.J., et al. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 128 (2005) 1453-1460
10. Jagadeeswaran R., Jagadeeswaran S., Bindokas V.P., and Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 292 (2007) L1488-L1494
11. Maulik G., Kijima T., Ma P.C., Ghosh S.K., Lin J., Shapiro G.I., et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8 (2002) 620-627
12. Ma P.C., Maulik G., Christensen J., and Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22 (2003) 309-325
13. Maulik G., Madhiwala P., Brooks S., Ma P.C., Kijima T., Tibaldi E.V., et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 6 (2002) 539-553
14. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65 (2005) 1479-1488
15. Sawada K., Radjabi A.R., Shinomiya N., Kistner E., Kenny H., Becker A.R., et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67 (2007) 1670-1679
16. Ke A.W., Shi G.M., Zhou J., Wu F.Z., Ding Z.B., Hu M.Y., et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology (2008) Epub ahead of print
17. Kong D.S., Song S.Y., Kim D.H., Joo K.M., Yoo J.S., Koh J.S., et al. Prognostic significance of c-Met expression in glioblastomas. Cancer 115 (2009) 140-148
18. Drebber U., Baldus S.E., Nolden B., Grass G., Bollschweiler E., Dienes H.P., et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19 (2008) 1477-1483
19. Yu L., Saile K., Swartz C.D., He H., Zheng X., Kissling G.E., et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 14 (2008) 264-275
20. Matsushita A., Gotze T., and Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res 67 (2007) 10309-10316
21. Timpson P., Wilson A.S., Lehrbach G.M., Sutherland R.L., Musgrove E.A., and Daly R.J. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 67 (2007) 9304-9314
22. Garcia S., Dales J.P., Charafe-Jauffret E., Carpentier-Meunier S., ndrac-Meyer L., Jacquemier J., et al. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31 (2007) 49-58
23. Garcia S., Dales J.P., Jacquemier J., Charafe-Jauffret E., Birnbaum D., ndrac-Meyer L., et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 96 (2007) 329-335
24. Natali P.G., Prat M., Nicotra M.R., Bigotti A., Olivero M., Comoglio P.M., et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 69 (1996) 212-217
25. Fischer J., Palmedo G., von Knobloch R., Bugert P., Prayer-Galetti T., Pagano F., et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17 (1998) 733-739
26. Tsao M.S., Liu N., Chen J.R., Pappas J., Ho J., To C., et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20 (1998) 1-16
27. Song L., Turkson J., Karras J.G., Jove R., and Haura E.B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22 (2003) 4150-4165
28. Gou S., Liu T., Wang C., Yin T., Li K., Yang M., et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 34 (2007) 429-435
29. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
30. Chen J.T., Lin T.S., Chow K.C., Huang H.H., Chiou S.H., Chiang S.F., et al. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol 34 (2006) 264-273
31. Maulik G., Shrikhande A., Kijima T., Ma P.C., Morrison P.T., and Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13 (2002) 41-59
32. Salgia R., Li J.L., Lo S.H., Brunkhorst B., Kansas G.S., Sobhany E.S., et al. Molecular cloning f human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem 270 (1995) 5039-5047
33. Playford M.P., and Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 23 (2004) 7928-7946
34. Mattiussi S., Matsumoto K., Illi B., Martelli F., Capogrossi M.C., and Gaetano C. Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. Cardiovasc Res 70 (2006) 578-588
35. Salgia R., Li J.L., Ewaniuk D.S., Wang Y.B., Sattler M., Chen W.C., et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 18 (1999) 67-77
36. Pasternak G., Hochhaus A., Schultheis B., and Hehlmann R. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol 124 (1998) 643-660
37. Dharmawardana P.G., Giubellino A., and Bottaro D.P. Hereditary papillary renal carcinoma type I. Curr Mol Med 4 (2004) 855-868
38. Salvi A., Marchina E., Benetti A., Grigolato P., De Petro G., and Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol 33 (2008) 271-276
39. Jagadeeswaran R., Surawska H., Krishnaswamy S., Janamanchi V., Mackinnon A.C., Seiwert T.Y., et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 68 (2008) 132-142
40. Siddiqui S.S., Loganathan S., Krishnaswamy S., Faoro L., Jagadeeswaran R., and Salgia R.C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther 7 (2008) 856-3
41. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452 (2008) 638-642
42. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452 (2008) 633-637
43. Reardon D.A., Cloughsey T.F., Raizer J.J., Laterra J., Schiff D., Tang X., et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme [abstract]. J Clin Oncol 26 (2008) 2051
44. Zillhardt M., Sawada K., Jagadeeswaran S., Temkin S., Yamada D., Buller R., et al. The c-Met/VEGFR2 inhibitor, XL880, inhibits ovarian cancer cell growth [abstract]. AACR Meeting Abstracts (2008) 4839
45. Clinical trials with AMG-102 as single agent or in combination in solid tumors. http://www.clinicaltrials.gov/ Accessed December 29, 2008
46. Clinical trials with small molecule inhibitors of c-Met (HGFR). http://www.clinicaltrials.gov/ Accessed December 29, 2008
47. Ma P.C., Tretiakova M.S., Nallasura V., Jagadeeswaran R., Husain A.N., and Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97 (2007) 368-377
48. Jagadeeswaran R, Puri N, Ma PC, Jagadeesh S, Schaefer E, Christensen J, et al. c-Met/HGF pathway and the role of reactive oxygen species in small cell lung cancer cells [abstract 429]. AACR Meeting Abstracts. 2004;42c.
49. Puri N, Ahmed S, Janamanchi V, Treitokova M, Krausz T, Jagadeeswaran R, et al. c-Met is a new therapeutic target for treatment of human melanoma [abstract]. AACR Meeting Abstracts. 2005;1406.
50. Puri N., and Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7 (2008) 9
51. Salgia R. c-Met receptor tyrosine kinase as a therapeutic target in cancer. American Society of Clinical Oncology Educational Book (2008) 113-118
52. Sattler M., Pisick E., Morrison P.T., and Salgia R. Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncol 11 (2000) 63-76